文献速递冠心病血脂与心血管预防

他汀时代的动脉粥样硬化斑块易损性

Atherosclerotic plaque vulnerability in the statin era.
PubMed 文献 · Eur Heart J · 2017-01-01

综述指出,生活方式改善和他汀等优化药物治疗已降低心血管死亡率,并使非ST段抬高型心肌梗死增多、组织学所见的易损斑块减少;但已确诊患者仍可复发心血管事件,可能与他汀仅控制脂质促炎效应、其他他汀不敏感机制随时间变得更重要有关。需更好理解斑块易损的替代机制,并开发新生物标志物、诊断方法和与现有治疗协同的新疗法。

要点

  • 他汀等优化治疗下已确诊患者仍可发生复发性心血管事件。
  • 组织学分析显示外科标本中易损斑块减少、非ST段抬高型心肌梗死增多。
  • 他汀可能仅控制脂质促炎效应,其他他汀不敏感机制随时间更重要。

核心结论

  • 他汀等现有治疗可能随时间对已确诊患者保护不足,需理解斑块易损的替代机制并开发协同新疗法。

研究设计与样本

  • 综述,未报告系统检索范围与样本量。

主要发现

  • 近几十年许多国家心血管死亡率下降,伴随非ST段抬高型心肌梗死增多和组织学分析外科标本中易损斑块减少。
  • 已确诊患者接受包括他汀的最先进治疗仍可复发心血管事件,可能反映他汀控制脂质促炎效应后其他他汀不敏感机制变得更重要。
  • 替代机制包括斑块狭窄所致血流模式改变使内皮抗炎和抗血栓信号下调、糖尿病相关血管修复受损、胆固醇结晶驱动的斑块炎症、感染病原体及针对修饰斑块成分的自身免疫反应。

临床怎么用

  • 需要新生物标志物和其他诊断方法来确定这些替代机制的临床重要性及其受当前治疗的影响。
  • 需要开发针对这些替代机制并与当前治疗协同的新疗法。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Life style changes and improved medical therapy have decreased cardiovascular mortality in many countries over the last decades. This has been accompanied by changes in disease characteristics including more non-ST segment elevation myocardial infraction and less vulnerable plaques as assessed by histological analysis of surgical specimens. However, many patients with established disease still suffer from recurrent cardiovascular events in spite of treatment with state-of-the-art-therapy including statins. It is likely that this reflects a state of the disease in which statins control the pro-inflammatory effects of lipids allowing other statin-unresponsive disease mechanisms to become increasingly important. If this assumption is correct it means that patients with established disease with time will get insuffient protection by current therapies alone. Against this background it is critical to reach a better understanding of alternative mechanisms for plaque vulnerability. Examples of such mechanisms include altered patterns of blood flow caused by plaque stenosis resulting in down-regulation of the anti-inflammatory and anti-thrombotic signals in the endothelium, impaired vascular repair associated with diabetes and plaque inflammation driven by cholesterol crystals, infectious pathogens as well as autoimmune responses against modified plaque components. Novel biomarkers and other diagnostics are needed to establish the clinical importance of these mechanisms as well as to determine how they are affected by current treatments. Consequently, there will also be a need for development of new treatments targeting these mechanisms and that can act in concert with current therapies.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Nilsson J. Atherosclerotic plaque vulnerability in the statin era. Eur Heart J. 2017. PMID: 28387815. doi:10.1093/eurheartj/ehx143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。